An interventional study of Group Metacognitive Therapy and Mindfulness Meditation Therapy in Generalized Anxiety Disorder, sponsored by University of Manchester. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-17.
Sponsored by University of Manchester · Not applicable, Interventional, and Treatment
The study will examine the effectiveness of group metacognitive therapy in comparison with group meditation therapy, in patients with Generalised Anxiety Disorder. Individuals will be randomly assigned to either meditation or metacognitive therapy and undergo 8 group therapy sessions of their respective treatment condition.
4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.
This study's enrollment of 40 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →University of Manchester is the lead sponsor of 194 studies on the registry; 43 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Individuals randomly assigned to the metacognitive therapy group will undergo group metacognitive therapy for generalized anxiety disorder.. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
Behavioral: Group Metacognitive Therapy
Individuals randomly assigned to the mindfulness meditation therapy group will undergo group mindfulness meditation therapy for generalized anxiety disorder. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
Behavioral: Mindfulness Meditation Therapy
Also known as: MCT
Also known as: MMT
Hospital Anxiety and Depression Scale (HADS)
Time frame: Administered at pre treatment, mid treatment, post treatment, and 6 month follow up
CAS-I
Time frame: Administered at pre treatment, mid treatment, post treatment, and 6 month follow up
GAD-7
Time frame: Completed prior to week 1 of treatment.This will be administered prior to treatment as a screening measure for levels of anxiety.
PHQ-9
Time frame: Completed prior to week 1 of treatment.This will be administered prior to treatment as a screening measure for levels of depression.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Manchester